NCT06278272

Brief Summary

Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients. A total of 504 patients with CP who underwent fecal elastase-1 test and contrast-enhanced CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. The investigators aim to establish a fully automated workflow to establish a PEI classification model based on radiomic features, semantic features and deep learning features on enhanced CT images for evaluating the severity of PEI.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
504

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2023

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

January 22, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 26, 2024

Completed
Last Updated

February 26, 2024

Status Verified

January 1, 2024

Enrollment Period

10 months

First QC Date

January 22, 2024

Last Update Submit

February 22, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Classification of pancreatic exocrine insufficiency

    Pancreatic exocrine insufficiency are classified by FE-1 test into severe (0-100), mild to moderate (100-200) and normal (\>200).

    Up to 10 months

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 504 patients with CP who underwent the FE-1 test and CE-CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. the exclusion criteria were as follows: (a) enhanced CT was taken during the acute episode of chronic pancreatitis, (b) history of malignant tumor, (c) previous pancreatic surgery, (4) systemic diseases, and (5) poor image quality or image loss

You may qualify if:

  • gender and age are not restricted
  • diagnosis of chronic pancreatitis
  • fe-1 test was conducted following recent pancreatic enhanced CT
  • sign informed consent

You may not qualify if:

  • enhanced CT was taken during the acute episode of chronic pancreatitis
  • history of malignant tumor
  • previous pancreatic surgery
  • systemic diseases
  • poor image quality or image loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changhai Hospital

Shanghai, 200433, China

Location

MeSH Terms

Conditions

Pancreatitis, ChronicExocrine Pancreatic Insufficiency

Condition Hierarchy (Ancestors)

PancreatitisPancreatic DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2024

First Posted

February 26, 2024

Study Start

March 1, 2023

Primary Completion

January 1, 2024

Study Completion

January 1, 2024

Last Updated

February 26, 2024

Record last verified: 2024-01

Locations